FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3152829069> ?p ?o ?g. }

• W3152829069 endingPage "474" @default.
• W3152829069 startingPage "471" @default.
• W3152829069 abstract "Background/Purpose: Filgotinib (FIL)—an oral, selective Janus kinase 1 inhibitor (JAKi)—improved RA signs and symptoms in three phase 3 trials. Despite the efficacy of FIL and other JAKi, there are some concerns regarding potential for venous thromboembolism (VTE); major adverse cardiac events (MACE); and elevated platelet levels, which may result from JAK2 inhibition and modulation of thrombopoietin and could be causally related to VTE.Methods: Patients (pts) meeting 2010 ACR/EULAR criteria for RA who participated in the phase 2 DARWIN 1–2 (D1–2), phase 3 FINCH 1–3 (F1–3), and long-term extension studies (DARWIN 3 [D3] and FINCH 4 [F4]) and received FIL 100 mg, FIL 200 mg, adalimumab (ADA), or placebo (PBO) with or without MTX were included. Events were analyzed as-exposed according to treatment received.The week (W)12 PBO-controlled safety analysis included data from pts who received FIL 100, FIL 200, or PBO for ≤12W (D1–2, F1–2); some PBO-treated pts had additional data through W24 (F1–2). The active-controlled analysis included data from pts who received FIL 100, FIL 200, or ADA with background MTX (F1) and pts who received FIL 100 + MTX, FIL 200 + MTX, FIL 200, or MTX (F3) for ≤52W. The FIL 200 vs FIL 100 analysis included data from pts (D1–3, F1–4) for ≤5.5 years.Data were analyzed based on whether pts did/did not experience a MACE or VTE event. For active-controlled analysis sets (except MACE in the MTX-controlled analysis set), exposure-adjusted incidence rates (EAIRs) and 95% confidence intervals (CIs) were calculated using the exact Poisson method, and treatment differences were provided with corresponding CIs based on the confidence limits of individual point estimates. For FIL 200 vs FIL 100 analyses and MACE in the MTX-controlled analysis set, EAIRs, difference in EAIRs, and 95% CIs were calculated using Poisson regression with treatment group as a covariate. Suspected MACE (cardiovascular [CV] death, myocardial infarction, and stroke) and VTE (deep vein thrombosis and pulmonary embolism) were adjudicated by a blinded independent CV safety endpoint adjudication committee.Results: CV risk factors were common at baseline (Table 1). No VTE occurred in the 12W PBO-controlled safety analysis (Figure 1). There were 13 total VTE events. EAIR/100 patient-years of exposure (PYE) were comparable for all treatments (EAIR [n]: FIL 200, 0.2 [7]; FIL 100, 0.1 [1]; ADA, 0.3 [1]; MTX, 0.5 [2]; PBO (up to W24), 0.7 [2]; Figure Figure 1. VTE events during the PBO-controlled, active-controlled, and long-term periods Figure 2. MACE during the PBO-controlled, active-controlled, and long-term periods 1). Crude incidence of MACE in the PBO-controlled safety analysis is shown in Figure 2. There were 32 MACE events overall. EAIRs were comparable for all treatments (EAIR [n]: FIL 200, 0.6 [16]; FIL 100, 0.6 [10]; ADA, 0.3 [1]; MTX, 0.5 [2]; PBO (up to W24), 1.0 [3]; Figure 2). Platelet counts did not increase during the study; at W52, mean platelet counts slightly decreased in all treatment arms.Conclusion: No safety signal for VTE or MACE was observed in the filgotinib RA program. EAIRs of positively adjudicated VTE and MACE were low and consistent with expectations in patients with RA (EAIR 0.4/100 PYE for VTE and 1.0/100 PYE for MACE)." @default.
• W3152829069 created "2021-04-26" @default.
• W3152829069 creator A5000754711 @default.
• W3152829069 creator A5006123817 @default.
• W3152829069 creator A5011826741 @default.
• W3152829069 creator A5019245481 @default.
• W3152829069 creator A5025160491 @default.
• W3152829069 creator A5027269428 @default.
• W3152829069 creator A5029356053 @default.
• W3152829069 creator A5029369824 @default.
• W3152829069 creator A5034591782 @default.
• W3152829069 creator A5047117557 @default.
• W3152829069 creator A5055154325 @default.
• W3152829069 creator A5059124438 @default.
• W3152829069 creator A5077155083 @default.
• W3152829069 creator A5080646462 @default.
• W3152829069 date "2020-01-01" @default.
• W3152829069 modified "2023-10-18" @default.
• W3152829069 title "Adjudicated MACE and VTE in the Filgotinib RA Program: Integrated Analysis from Phase 2 and 3 Clinical Trials" @default.
• W3152829069 hasPublicationYear "2020" @default.
• W3152829069 type Work @default.
• W3152829069 sameAs 3152829069 @default.
• W3152829069 citedByCount "0" @default.
• W3152829069 crossrefType "journal-article" @default.
• W3152829069 hasAuthorship W3152829069A5000754711 @default.
• W3152829069 hasAuthorship W3152829069A5006123817 @default.
• W3152829069 hasAuthorship W3152829069A5011826741 @default.
• W3152829069 hasAuthorship W3152829069A5019245481 @default.
• W3152829069 hasAuthorship W3152829069A5025160491 @default.
• W3152829069 hasAuthorship W3152829069A5027269428 @default.
• W3152829069 hasAuthorship W3152829069A5029356053 @default.
• W3152829069 hasAuthorship W3152829069A5029369824 @default.
• W3152829069 hasAuthorship W3152829069A5034591782 @default.
• W3152829069 hasAuthorship W3152829069A5047117557 @default.
• W3152829069 hasAuthorship W3152829069A5055154325 @default.
• W3152829069 hasAuthorship W3152829069A5059124438 @default.
• W3152829069 hasAuthorship W3152829069A5077155083 @default.
• W3152829069 hasAuthorship W3152829069A5080646462 @default.
• W3152829069 hasConcept C126322002 @default.
• W3152829069 hasConcept C142724271 @default.
• W3152829069 hasConcept C197934379 @default.
• W3152829069 hasConcept C204787440 @default.
• W3152829069 hasConcept C27081682 @default.
• W3152829069 hasConcept C2780400711 @default.
• W3152829069 hasConcept C2780739214 @default.
• W3152829069 hasConcept C500558357 @default.
• W3152829069 hasConcept C71924100 @default.
• W3152829069 hasConceptScore W3152829069C126322002 @default.
• W3152829069 hasConceptScore W3152829069C142724271 @default.
• W3152829069 hasConceptScore W3152829069C197934379 @default.
• W3152829069 hasConceptScore W3152829069C204787440 @default.
• W3152829069 hasConceptScore W3152829069C27081682 @default.
• W3152829069 hasConceptScore W3152829069C2780400711 @default.
• W3152829069 hasConceptScore W3152829069C2780739214 @default.
• W3152829069 hasConceptScore W3152829069C500558357 @default.
• W3152829069 hasConceptScore W3152829069C71924100 @default.
• W3152829069 hasLocation W31528290691 @default.
• W3152829069 hasOpenAccess W3152829069 @default.
• W3152829069 hasPrimaryLocation W31528290691 @default.
• W3152829069 hasRelatedWork W1623985254 @default.
• W3152829069 hasRelatedWork W2111683629 @default.
• W3152829069 hasRelatedWork W2142330200 @default.
• W3152829069 hasRelatedWork W2311408877 @default.
• W3152829069 hasRelatedWork W2312673012 @default.
• W3152829069 hasRelatedWork W2327716072 @default.
• W3152829069 hasRelatedWork W2328125605 @default.
• W3152829069 hasRelatedWork W2521130950 @default.
• W3152829069 hasRelatedWork W2550603140 @default.
• W3152829069 hasRelatedWork W2594023064 @default.
• W3152829069 hasRelatedWork W2756380549 @default.
• W3152829069 hasRelatedWork W2792460055 @default.
• W3152829069 hasRelatedWork W2906073625 @default.
• W3152829069 hasRelatedWork W2944352931 @default.
• W3152829069 hasRelatedWork W2970739501 @default.
• W3152829069 hasRelatedWork W3096295699 @default.
• W3152829069 hasVolume "72" @default.
• W3152829069 isParatext "false" @default.
• W3152829069 isRetracted "false" @default.
• W3152829069 magId "3152829069" @default.
• W3152829069 workType "article" @default.